Table 1 clinicopathologic features in 12 patients with GIST
Characteristic | Primary lesions | Post-drug resistance | p |
|---|---|---|---|
n | 9 | 9 | |
T stage, n (%) | 0.813 | ||
T1 | 2 (11.1%) | 2 (11.1%) | |
T2 | 4 (22.2%) | 6 (33.3%) | |
T3 | 2 (11.1%) | 1 (5.6%) | |
T4 | 1 (5.6%) | 0 (0%) | |
M stage, n (%) | 0.082 | ||
M0 | 9 (50%) | 5 (27.8%) | |
M1 | 0 (0%) | 4 (22.2%) | |
Pathology, n (%) | 0.058 | ||
Ib | 0 (0%) | 1 (5.6%) | |
II | 5 (27.8%) | 4 (22.2%) | |
IIIa | 3 (16.7%) | 0 (0%) | |
IIIb | 1 (5.6%) | 0 (0%) | |
IV | 0 (0%) | 4 (22.2%) | |
Gender, n (%) | 1.000 | ||
Female | 3 (16.7%) | 3 (16.7%) | |
Male | 6 (33.3%) | 6 (33.3%) | |
Mitotic count(< 5/50HPF或 > 10/50HPF), n (%) | 1.000 | ||
High | 7 (38.9%) | 7 (38.9%) | |
Low | 2 (11.1%) | 2 (11.1%) | |
Tumor site, n (%) | 0.156 | ||
Mesenterium | 0 (0%) | 1 (5.6%) | |
Omentum | 0 (0%) | 2 (11.1%) | |
Peritoneum | 0 (0%) | 1 (5.6%) | |
Rectum | 1 (5.6%) | 0 (0%) | |
Small intestine | 3 (16.7%) | 0 (0%) | |
Stomach | 5 (27.8%) | 5 (27.8%) | |
Age, mean ± SD | 53.78 ± 5.74 | 58.78 ± 8.18 | 0.153 |